Mitsuhiro Yuasa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitsuhiro Yuasa has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Junji Koya
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
24 shared publications - Keisuke Kataoka
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
24 shared publications - Mariko Tabata
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
24 shared publications - Sumito Shingaki
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
24 shared publications - Yasunori Kogure
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
24 shared publications - Yuki Saito
Division of Molecular Oncology National Cancer Center Research Institute Tokyo Japan
24 shared publications
Latest Publications
- 29 October 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Neutrophil Engraftment Timing After Single-unit Cord Blood Transplantation as a Prognostic Marker of Transplant Outcomes Influenced by GVHD Prophylaxis: A Nationwide, Retrospective Study by the Japanese Society for Transplantation and Cellular Therapy
- 29 October 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Neutrophil Engraftment Timing After Single-unit Cord Blood Transplantation as a Prognostic Marker of Transplant Outcomes Influenced by GVHD Prophylaxis: A Nationwide, Retrospective Study by the Japanese Society for Transplantation and Cellular Therapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- Open Access
- 26 May 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
Ultrastructural features of early T-precursor acute lymphoblastic leukemia
- 26 May 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
Open AccessUltrastructural features of early T-precursor acute lymphoblastic leukemia
- 14 May 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (7) , 1537-1547
Integration of peripheral blood lymphocyte count kinetics and bone marrow hematogones for stratifying B-cell recovery and clinical outcomes after cord blood transplantation: a retrospective study
Delayed immune reconstitution is a notable concern of allogeneic hematopoietic stem cell transplantation (SCT) as it leads to a high non-relapse mortality (NRM) rate [1], thus highlighting the impo...
- 14 May 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (7) , 1537-1547
Integration of peripheral blood lymphocyte count kinetics and bone marrow hematogones for stratifying B-cell recovery and clinical outcomes after cord blood transplantation: a retrospective study
Delayed immune reconstitution is a notable concern of allogeneic hematopoietic stem cell transplantation (SCT) as it leads to a high non-relapse mortality (NRM) rate [1], thus highlighting the impo...
- Open Access
- 14 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 5040-5055
In vivo CRISPR screening reveals cooperation of KMT2D and TP53 deficiencies in B-cell lymphomagenesis
Although recent genetic studies have identified numerous genetic alterations in diffuse large B-cell lymphoma (DLBCL), their biological relevance remains elusive. Here, we performed in vivo CRISPR loss-of-function screening targeting 86 genes recurrently altered in DLBCL to examine oncogenicity of single-guide RNA (sgRNA)–targeted genes, association between genotype and lineage, occurrence of second-hit alterations, and cooperability among sgRNA-targeted genes and second-hit alterations. Transplantation of the CRISPR library–transduced hematopoietic stem/progenitor cells induces various hematologic malignancies, including B-cell lymphomas in mice. Enrichment analysis of sgRNA-targeted genes demonstrates significant overrepresentation of Kmt2d, Pax5, and Trp53 in B-cell lymphomas. Whole-exome sequencing identifies recurrent second-hit driver alterations, showing significant enrichment of Trp53 alterations in sgKmt2d-targeted B-cell lymphomas. Importantly, KMT2D and TP53 mutations are found to be the most prevalent co-occurring combination in human DLBCL, which is more prominent in relapsed/refractory DLBCL. Moreover, this combination confers significantly worse prognosis independent of clinical factors. Transcriptomic sequencing identifies overexpression of Yap1, the Hippo pathway component, in double sgKmt2d-targeted/Trp53-altered B-cell lymphomas. Furthermore, chromatin accessibility analysis demonstrates enrichment of transcriptional enhanced associate domain 1 binding motifs in regions that gained accessibility and increased expression of their nearest genes in these B-cell lymphomas. Most importantly, genetic and pharmacological inhibition of YAP1 suppresses in vitro cell proliferation and in vivo tumor growth of a human KMT2D/TP53-altered DLBCL cell line and prolongs survival of mice transplanted with double sgKmt2d-targeted/Trp53-altered B-cell lymphoma cells. Our findings demonstrate the utility of in vivo CRISPR screening to integrate human cancer genomics with mouse modeling and highlight the functional interplay between KMT2D and TP53 aberrations, providing insights into therapeutic strategies in DLBCL.
- 14 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 5040-5055
Open AccessIn vivo CRISPR screening reveals cooperation of KMT2D and TP53 deficiencies in B-cell lymphomagenesis
Although recent genetic studies have identified numerous genetic alterations in diffuse large B-cell lymphoma (DLBCL), their biological relevance remains elusive. Here, we performed in vivo CRISPR loss-of-function screening targeting 86 genes recurrently altered in DLBCL to examine oncogenicity of single-guide RNA (sgRNA)–targeted genes, association between genotype and lineage, occurrence of second-hit alterations, and cooperability among sgRNA-targeted genes and second-hit alterations. Transplantation of the CRISPR library–transduced hematopoietic stem/progenitor cells induces various hematologic malignancies, including B-cell lymphomas in mice. Enrichment analysis of sgRNA-targeted genes demonstrates significant overrepresentation of Kmt2d, Pax5, and Trp53 in B-cell lymphomas. Whole-exome sequencing identifies recurrent second-hit driver alterations, showing significant enrichment of Trp53 alterations in sgKmt2d-targeted B-cell lymphomas. Importantly, KMT2D and TP53 mutations are found to be the most prevalent co-occurring combination in human DLBCL, which is more prominent in relapsed/refractory DLBCL. Moreover, this combination confers significantly worse prognosis independent of clinical factors. Transcriptomic sequencing identifies overexpression of Yap1, the Hippo pathway component, in double sgKmt2d-targeted/Trp53-altered B-cell lymphomas. Furthermore, chromatin accessibility analysis demonstrates enrichment of transcriptional enhanced associate domain 1 binding motifs in regions that gained accessibility and increased expression of their nearest genes in these B-cell lymphomas. Most importantly, genetic and pharmacological inhibition of YAP1 suppresses in vitro cell proliferation and in vivo tumor growth of a human KMT2D/TP53-altered DLBCL cell line and prolongs survival of mice transplanted with double sgKmt2d-targeted/Trp53-altered B-cell lymphoma cells. Our findings demonstrate the utility of in vivo CRISPR screening to integrate human cancer genomics with mouse modeling and highlight the functional interplay between KMT2D and TP53 aberrations, providing insights into therapeutic strategies in DLBCL.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends